Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brett W Carter

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Nature Communications|May 13, 2021
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinomaXin Hu, Junya Fujimoto, Lisha Ying, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Nature Communications|July 7, 2019
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinomaXin Hu, Junya Fujimoto, Lisha Ying, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.
Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.
Nature Communications|May 13, 2021
Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinomaXin Hu, Junya Fujimoto, Lisha Ying, et al.
Cancer Discovery|July 18, 2018
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 BlockadeLimo Chen, Lixia Diao, Yongbin Yang, et al.
Journal for Immunotherapy of Cancer|October 24, 2024
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancerNicolas Zhou, Cheuk H Leung, William N William, et al.
Nature Communications|July 7, 2019
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinomaXin Hu, Junya Fujimoto, Lisha Ying, et al.
The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
Nature Medicine|March 17, 2023
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trialTina Cascone, Cheuk H Leung, Annikka Weissferdt, et al.
Pageof 18